50% off Premium Yearly
Agilent TechnologiesAPAST TOP PICKOct 13, 2023Stock price when the opinion was issued
As of Jun 12, 2026. Market Open.
Is up 55% from its April lows. They just reported a strong quarter with 7% organic growth. The business is turning around, helped by re-shoring in life sciences, plus the rise of some medicine that require more hardware to produce. The FDA is less disruptive as expected. The life sciences sector looks attractive.
Sector has been impacted with economic slow down after Covid-19. Believes healthcare sector will be strong in the long term. Lab tools in high demand globally. Will continue to own shares. Well managed company.